<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="16247">Phospholipid</z:chebi> scramblase 1 (PLSCR1) not only participates in the transbilayer movement of <z:chebi fb="1" ids="16247">phospholipids</z:chebi>, but also plays a role in the pathogenesis and progression of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The present study aimed to evaluate the effect of silencing PLSCR1 expression by <z:chebi fb="40" ids="33697">RNA</z:chebi> interference in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) and metastatic <z:hpo ids='HP_0002896'>liver cancer</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: The expression of PLSCR1 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and metastatic <z:hpo ids='HP_0002896'>liver cancer</z:hpo> samples was assessed by immunohistochemistry </plain></SENT>
<SENT sid="3" pm="."><plain>The cultured cells with the highest expression were selected for subsequent experiments </plain></SENT>
<SENT sid="4" pm="."><plain>We designed three siRNA oligonucleotide segments targeted at PLSCR1 </plain></SENT>
<SENT sid="5" pm="."><plain>Successful transfection was confirmed </plain></SENT>
<SENT sid="6" pm="."><plain>The biological behavior of the cells in proliferation, <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e>, migration and invasion was determined </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: PLSCR1 protein expression increased significantly in the majority of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and metastatic <z:hpo ids='HP_0002896'>liver cancer</z:hpo> samples compared with <z:mpath ids='MPATH_458'>normal</z:mpath> samples </plain></SENT>
<SENT sid="8" pm="."><plain>Lovo cells had the highest expression of PLSCR1 </plain></SENT>
<SENT sid="9" pm="."><plain>The siRNA-390 oligonucleotide segment had the best silencing effect </plain></SENT>
<SENT sid="10" pm="."><plain>After transfection, Lovo cell proliferation was significantly inhibited compared with the controls in the <z:chebi fb="0" ids="53233">MTT</z:chebi> assay </plain></SENT>
<SENT sid="11" pm="."><plain>Laminin and fibronectin <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> assays showed Lovo cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> was also significantly inhibited </plain></SENT>
<SENT sid="12" pm="."><plain>In the migration assay, the number of migrating cells in the PLSCR1 siRNA-390 group was 50+/-12, significantly lower than the number in the siRNA-N group (115+/-28) and in the control group (118+/-31) </plain></SENT>
<SENT sid="13" pm="."><plain>In an invasion test, the number of invading cells in the PLSCR1 siRNA-390 group was 60+/-18, significantly lower than that in the siRNA-N group (97+/-26) and the control group (103+/-24) </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: PLSCR1 is overexpressed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and metastatic <z:hpo ids='HP_0002896'>liver cancer</z:hpo> </plain></SENT>
<SENT sid="15" pm="."><plain>Silencing of PLSCR1 by siRNA inhibits the proliferation, <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e>, migration and invasion of Lovo cells, which suggests that PLSCR1 contributes to the <z:mp ids='MP_0002006'>tumorigenesis</z:mp> and <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="16" pm="."><plain>PLSCR1 may be a potential gene therapy target for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and associated metastatic <z:hpo ids='HP_0002896'>liver cancer</z:hpo> </plain></SENT>
</text></document>